Antimigraine drugs are medications intended to reduce the effects or intensity of migraine headache.

[1] Examples of specific antimigraine drug classes include triptans (first line option), ergot alkaloids, ditans and gepants.

[2] Due to their safety, efficacy and selectivity, triptans are considered first line agents for abortion of migraines.

They produce an antimigraine effect by vasoconstriction of the vessels in the brain, as well as inhibiting trigeminal CGRP release and pain transmission.

[3] Triptans use is limited to less than ten times per month in order to reduce Medication Overuse Headache (MOH).

This medication class targets the CGRP receptor pathway due to their likeness to serotonin, dopamine and noradrenaline.

[2] Their use is limited to less than ten times per month in order to reduce medication overuse headaches (MOH's).

lasmiditan) are a new group of anti migraine drugs which were developed due some of the concerns with the 1st line triptans (eg.

[7] Lasmiditan has been suggested to have less pain relief when compared to the triptans at the 2 hour mark post taking the medication.

Lasmiditan was shown to have higher adverse events (dizziness, fatigue and nausea) than the triptans or another novel medication class, CGRP antagonists.

Similar to ditans, they offer another therapy option that does not include vasoconstriction, thus may be suitable for those with cardiovascular risk factors.

[8] Opioids are not recommended for treatment of acute migraines due to their significant side effect profile, including twice the risk of medication overuse headache when compared to NSAIDS, acetaminophen or triptans.

[10] Adverse events of antidepressants can include fatigue, nausea, drowsiness, dizziness, dry mouth, GI upset and weakness.

[14] Erenumab is a highly selective human monoclonal antibody which is a promising new development in migraine treatment.